Moneycontrol
HomeNewsBusinessCompaniesPrice cap, concentration on metros dash hospital chains’ revenue recovery hopes from COVID-19 treatment
Trending Topics

Price cap, concentration on metros dash hospital chains’ revenue recovery hopes from COVID-19 treatment

With cases in metros coming down, large hospitals with less than 50% occupancy want to reallocate COVID beds to non-COVID patients. But regulations prevent them from doing so. Hospitals complain rates fixed by the govt are very low and do not even cover the cost of treatment.

August 27, 2020 / 19:22 IST
Story continues below Advertisement
Representative image

Large private hospital chains, which were hoping to recoup some of their losses by allocating some beds to COVID-19 patients, have hit a wall, owing to under-utilisation of bed capacities and lower realisations.

Though most hospitals now want to reallocate COVID beds to non-COVID patients, regulations and infection protocols prevent them from doing so.

Story continues below Advertisement

The hopes of hospital chains that COVID treatment will add to revenues dashed primarily because of the price caps by the government. Also, many large chains are concentrated in big cities, and most COVID cases are now being reported from Tier-II cities and smaller towns.

Max Healthcare Institute, India's second-largest hospital chain, says currently less than half the COVID beds are occupied.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show